SFMS Announces Investigation Into Gentiva Health Services’ Acquisition Of Odyssey Healthcare
Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) ( http://www.sfmslaw.com) is investigating the agreement under which Gentiva Health Services (“Gentiva”) (Nasdaq: GTIV) intends to acquire Odyssey Healthcare, Inc. (“Odyssey Healthcare”) (Nasdaq: ODSY). Odyssey Healthcare, based in Dallas, Texas, provides hospice care for patients. Gentiva, with headquarters in Atlanta, Georgia, provides home health services. The agreement, announced on May 24, 2010, would allow Gentiva to acquire Odyssey Healthcare for $27.00 per share, or approximately $1.1 billion for the transaction. SFMS’ investigation of the agreement concerns whether there has been adequate disclosure to shareholders concerning the terms of the acquisition and whether the compensation offered to Odyssey Healthcare shareholders pursuant to the acquisition is adequate. The transaction is expected to be completed in the third quarter of 2010.
If you own shares of Odyssey Healthcare and would like to request additional information about this investigation, please contact Karen M. Leser-Grenon at kleser@sfmslaw.com or toll-free at 866-540-5505 (ext. 206) or Patrick A. Klingman at pklingman@sfmslaw.com or toll-free at 866-540-5505 (ext. 205).
Shepherd, Finkelman, Miller & Shah, LLP ( http://www.sfmslaw.com) is a law firm that represents consumers, fiduciaries, beneficiaries and investors, including institutions and individuals, in class action and other complex litigation, and maintains offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin. The firm’s attorneys have experience prosecuting cases on behalf of shareholders in mergers and acquisitions throughout the United States.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
